Targeting vascular endothelial growth factor (VEGF) pathway represents a successful
strategy in the treatment of metastatic colorectal cancer (mCRC). Since the approval of the …

Bevacizumab, the first approved vascular endothelial growth factor (VEGF)–targeted agent
for metastatic colorectal cancer, continues to be developed in phase III trials in other tumor …

The process of new blood vessel formation, or angiogenesis, has become an important
target for therapeutic intervention in many cancers, including metastatic colorectal cancer …

Targeting tumor-driven angiogenesis is an effective strategy in the management of
metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is …

Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial
growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of …

Continuation of anti-angiogenic agents beyond progression in second-line therapy is
recognized as a standard of care for patients with metastatic colorectal cancer, and there are …

Introduction: Targeted agents have dramatically improved and enriched the therapeutical
choices for patients with metastatic colorectal cancer (mCRC). By better understanding the …

Targeting angiogenesis represents a key element in the overall treatment strategy and
angiogenesis inhibition is in general clinically effective and has an important place in the …

Ten years after the approval of bevacizumab in colorectal cancer patients, results from
ML18147 and CORRECT studies have recently demonstrated the possibility to target …

Opinion statement Metastatic cancer was previously treated with distinctive lines of
chemotherapy regimens upon disease progression or toxicity, yet the choices of therapy are …